Selected data models

You must log in to select data models for download or further analysis.

25 Search results.
Relevance Rating New first Old first

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Visit 03

- 10/22/18 - 1 form, 2 itemgroups, 5 items, 1 language
Itemgroups: Follow-Up, Patient Discharge
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; NCT - Hospital Discharge Visit

- 9/20/21 - 1 form, 5 itemgroups, 43 items, 1 language
Itemgroups: Administrative Data, Discharge Status, Hospitals, Adverse Event, Interventional procedure, Since, Percutaneous Coronary Intervention, Concomitant Agent
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; NCT - Hospital Discharge Visit

- 9/20/21 - 1 form, 5 itemgroups, 39 items, 1 language
Itemgroups: Administrative Data, Follow-Up Visit, Adverse Event, Interventional procedure, Since, Percutaneous Coronary Intervention, Concomitant Agent
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Study ID: 104574 - Re-Intervention Report

- 9/20/21 - 1 form, 5 itemgroups, 50 items, 1 language
Itemgroups: Administrative Data, Interventional Procedure; Report, Coronary Angiography, Repeat Surgery; Percutaneous Coronary Intervention, Coronary Artery Bypass Surgery
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Assessment of Suspected Pulmonary Embolism

- 11/6/18 - 1 form, 9 itemgroups, 32 items, 1 language
Itemgroups: Pulmonary Embolism, Suspicion, Pulmonary Embolism; Lung Scan, Ultrasonography, Venography, Angiogram, Tomography, Spiral Computed, Other Tests, Therapeutic Procedure, Pulmonary Embolism, Seriousness
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Adverse Event Form

- 11/6/18 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Adverse Event
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Visit 02

- 10/22/18 - 1 form, 5 itemgroups, 35 items, 1 language
Itemgroups: Experimental Drug, Dosage, Hematology finding, Biochemistry, Venography, Prophylactic treatment, Mechanical Methods; Physical therapy
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Visit 01

- 10/22/18 - 1 form, 9 itemgroups, 69 items, 1 language
Itemgroups: Operative Surgical Procedures; Details, Hematology finding, Inclusion, Exclusion Criteria, Inclusion, Exclusion Criteria, Therapeutic procedure, Assignment, Exclusion Criteria, Therapeutic Procedures, Assignment
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; NCT - Index PCI Form

- 9/30/18 - 1 form, 4 itemgroups, 70 items, 1 language
Itemgroups: Administrative Data, History of percutaneous coronary intervention, Culprit lesion of coronary artery, Coronary angiography, Result, During Index PCI, Laboratory, Status post, Percutaneous Coronary Intervention; Electrocardiography, Status post; Percutaneous Coronary Intervention
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Study ID: 104574 - Blinded Anticoagulation Form

- 8/28/18 - 1 form, 3 itemgroups, 9 items, 1 language
Itemgroups: Administrative Data, Study Drug Accountability, ACT Measurement
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Study ID: 104574 - Baseline Form

- 8/28/18 - 1 form, 5 itemgroups, 62 items, 1 language
Itemgroups: Administrative Data, Patient Information, Clinical Assessment Pre-Randomization, Pre-Randomization Laboratory Tests, Patient History
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Fondaparinux sodium (Arixtra) versus unfractionated heparin with patients undergoing PCI; Clinical Study ID: AR1104574 - MI Report

- 8/13/18 - 1 form, 4 itemgroups, 25 items, 1 language
Itemgroups: Administrative Data, Myocardial Infarction, Cardiac enzymes; Cardiac markers , Myocardial Infarction consequences
Study ID: 104574 Clinical Study ID: AR1104574 Study Title: A randomized blinded pilot trial of fondaparinux sodium (Arixtra®) versus unfractionated heparin in addition to standard therapy in a broad range of patients undergoing percutaneous coronary intervention (ASPIRE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thromboembolism

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial